BridgeBio Pharma, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| BridgeBio Pharma, Inc. | BBIO - NASDAQ |
$14.00-$16.00 | $17.00 | $30.61 | 20.5 million | 6/27/2019 |
| J.P. Morgan, Goldman Sachs & Co, Jefferies, SVB Leerink, KKR | ||||||
Co-Manager(s): Piper Jaffray, Mizuho Securities, BMO Capital Markets, Raymond James | ||||||
| Health Care | ||||||
Filing(s): Filed 2019-05-24 Terms Added 2019-06-17 Terms Changed 2019-06-26 | ||||||
BridgeBio Pharma, Inc. Quote & Chart - Click for current quote - BBIO
IPO Boutique aggregates information on public companies and private companies, such as "BBIO" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About BridgeBio Pharma, Inc. (adapted from BridgeBio Pharma, Inc. prospectus):
They are a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "BBIO" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.